Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Head & Neck 1Genitourinary 1Gastrointestinal 1

Conditions

Melanoma 7Neoplasms 4Advanced Cancer 4Lymphoma, Non-Hodgkin 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Lymphoma, Large B-Cell, Diffuse 2Liver Neoplasms 2Hodgkin Disease 2Various Advanced Cancer 1Uveal Melanoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms by Site 1Microsatellite Unstable Colorectal Cancer 1Melanoma, Cutaneous Malignant 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Burkitt Lymphoma 1Advanced Solid Tumors 1

Interventions

Carboplatin 367Pemetrexed 308pembrolizumab 302Cisplatin 242Paclitaxel 230Docetaxel 199Gemcitabine 130Nivolumab 121Erlotinib Hydrochloride 114Bevacizumab 85osimertinib 78atezolizumab 65durvalumab 58Cetuximab 57130-nm albumin-bound paclitaxel 56Gefitinib 52Ipilimumab 46Afatinib 38Drug Therapy 33Cyclophosphamide 30Crizotinib 30Albumin-Bound Paclitaxel 30Vinorelbine 28cemiplimab 26tislelizumab 25avelumab 23icotinib 22Radiotherapy 22capmatinib 21Oxaliplatin 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Non-Small-Cell Lung × relatlimab × Clear all
NCT05176483 2026-05-27

STELLAR-002

Exelixis

Phase 1 Recruiting
1,314 enrolled
GastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT06561386 2026-05-20

RELATIVITY1093

Bristol-Myers Squibb

Phase 3 Recruiting
1,000 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04623775 2025-10-20

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Bristol-Myers Squibb

Phase 2 Active not recruiting
468 enrolled 24 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡